<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; gene</title>
	<atom:link href="http://www.tapanray.in/tag/gene/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Collaboration For Sustainable Excellence – The Name of The Game in The New Normal</title>
		<link>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal</link>
		<comments>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 May 2023 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[digital tools]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[new therapeutics]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10785</guid>
		<description><![CDATA[The union minister of health and family welfare of India recently invited Japanese companies to collaborate with Indian companies on research and innovation in emerging therapies, like precision medicine, cell and gene therapy, biological products, and on the utilization of &#8230; <a href="http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Integrity Issue Haunts Again With Covid Vaccine?</title>
		<link>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-integrity-issue-haunts-again-with-covid-vaccine</link>
		<comments>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/#comments</comments>
		<pubDate>Mon, 29 Mar 2021 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[ghosts]]></category>
		<category><![CDATA[haunts. AstraZeneca]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10454</guid>
		<description><![CDATA[On March 22, 2021, by a media release, AstraZeneca announced that its ‘US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% in preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.’ Quite unexpectedly, on March &#8230; <a href="http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-integrity-issue-haunts-again-with-covid-vaccine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Any Threat To Current Commercial Model Of ‘Gene Therapy’?</title>
		<link>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=any-threat-to-current-commercial-model-of-gene-therapy</link>
		<comments>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/#comments</comments>
		<pubDate>Mon, 30 Dec 2019 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CAR-T]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[current]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[disorders]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genetic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9833</guid>
		<description><![CDATA[Wish All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2020 &#160; One of the most complex areas in disease management, is the ailments related to genetic disorders. As these were incurable, over the last four decades, medical researchers &#8230; <a href="http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>On The Flip Side of Pharma Industry: A Saga of Perennial Contradictions</title>
		<link>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions</link>
		<comments>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/#comments</comments>
		<pubDate>Mon, 09 Dec 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEOs]]></category>
		<category><![CDATA[contradiction]]></category>
		<category><![CDATA[contradictions]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[flip]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[perennial]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[side]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vice versa]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9804</guid>
		<description><![CDATA[Awesome contribution in the battle against multiple diseases, is obviously the primary facet of the pharma industry. However, on its flip side, one would witness a saga of numerous contradictions. Some of these exist perennially in well-protected opaque cocoons, regardless &#8230; <a href="http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A New Facet of ‘Data Integrity’ With Novel Therapy… And Much Beyond</title>
		<link>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond</link>
		<comments>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/#comments</comments>
		<pubDate>Mon, 30 Sep 2019 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AveXis]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[cherry-picking]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9728</guid>
		<description><![CDATA[The peril of breach of data integrity involving a top Indian pharma player, jolted many, probably for the first time, on September 17, 2008. On that day, the USFDA, reportedly, issued two ‘Warning Letters’ and an ‘Import Alert’. These were related to &#8230; <a href="http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gene Therapy Price: Commercial Viability And Moral Dilemma</title>
		<link>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gene-therapy-price-commercial-viability-and-moral-dilemma</link>
		<comments>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/#comments</comments>
		<pubDate>Mon, 17 Jun 2019 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercially]]></category>
		<category><![CDATA[dilemma]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[moral]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Spinraza]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[viability.]]></category>
		<category><![CDATA[viable]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9586</guid>
		<description><![CDATA[On May 24, 2019, Novartis announced the US-FDA approval of ‘the first and only gene therapy’ – Zolgensma, for a type of Spinal Muscular Atrophy (SMA), a lifesaving treatment for infants of less than 2 years of age. This unique drug halts disease progression &#8230; <a href="http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Disruptive Innovation to Fight and Cure Intractable Diseases</title>
		<link>http://www.tapanray.in/a-disruptive-innovation-to-fight-and-cure-intractable-diseases/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-disruptive-innovation-to-fight-and-cure-intractable-diseases</link>
		<comments>http://www.tapanray.in/a-disruptive-innovation-to-fight-and-cure-intractable-diseases/#comments</comments>
		<pubDate>Sun, 29 Oct 2017 23:44:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[encoding]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[Glybera]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intractable]]></category>
		<category><![CDATA[Kymriah]]></category>
		<category><![CDATA[Luxturna]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Yescarta]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8483</guid>
		<description><![CDATA[Several important facets of health care often arrest general attention. These are also widely discussed, analyzed and argued vehemently &#8211; with each person or group trying to justify one’s own point of view. Among these, following 6 critical areas, broadly &#8230; <a href="http://www.tapanray.in/a-disruptive-innovation-to-fight-and-cure-intractable-diseases/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-disruptive-innovation-to-fight-and-cure-intractable-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Evolving Paradigm of ‘Price-Value Model’ Of Pharma Value Delivery System</title>
		<link>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system</link>
		<comments>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/#comments</comments>
		<pubDate>Mon, 09 May 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[alipogene]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[Glybera]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[map]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Price-Value]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[tiparvovec)]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7631</guid>
		<description><![CDATA[May 4, 2016 edition of the ‘MIT Technology Review’ published an interesting article carrying the headline, “The World’s Most Expensive Medicine Is a Bust”. The obvious question that floats at the top of mind: What is this most expensive drug &#8230; <a href="http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-evolving-paradigm-of-price-value-model-of-pharma-value-delivery-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer Cure: Inching Towards The ‘Holy Grail’?</title>
		<link>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cancer-cure-inching-towards-the-holy-grail</link>
		<comments>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/#comments</comments>
		<pubDate>Mon, 31 Aug 2015 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Carter]]></category>
		<category><![CDATA[cells]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[former]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Holy-Grail]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jimmy]]></category>
		<category><![CDATA[magic bullet]]></category>
		<category><![CDATA[Mayo Clinic]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[programming]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[re-programming]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6992</guid>
		<description><![CDATA[In a Press Conference on August 20, 2015, the 39th President of the United States, now 90-year-old  Jimmy Carter, revealed (video) that during a liver surgery earlier this month the doctors diagnosed that he has cancer. The type of cancer that he &#8230; <a href="http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Disruptive Innovation in Healthcare &#8211; Personalized Medicines</title>
		<link>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-disruptive-innovation-in-healthcare-personalized-medicines</link>
		<comments>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/#comments</comments>
		<pubDate>Mon, 21 Mar 2011 01:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Personalized. Medicines]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=287</guid>
		<description><![CDATA[Tufts Center for the Study of Drug Development (Tufts University) in its publication named ‘Impact Report’, November/December 2010 articulated, “Biopharmaceutical companies are committed to researching and developing personalized medicines and within their development pipelines, 12%-50% of compounds are personalized medicines.” &#8230; <a href="http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
